West Brom Building Society Announces Major Digital Transformation with Deloitte and 10x Banking
LONDON--(BUSINESS WIRE)-- West Brom Building Society, the UK's eighth largest building society is embarking on its digital transformation journey working with the technology team at Deloitte, the professional services firm and 10x Banking, the cloud-native meta core banking platform.
West Brom Building Society is pleased to be working with Deloitte and 10x to deliver the next stage of its digital transformation, putting the right technology in place to continue providing excellent service to its customers in a digital world. The transformation programme will ensure the business continues to meet the evolving needs of its customers, around choice, flexibility and the ability to access services in the way that suits them best.
The news comes as the building society sector prepares to mark its 250th anniversary at the 2025 Building Societies Annual Conference, highlighting the pressing need for mutuals to innovate through modernising their technology and delivering on their purpose, in a world increasingly driven by digital customer experience and AI enhanced business processes.
Jonathan Westhoff, Chief Executive Officer, West Brom Building Society said: 'We chose to work with Deloitte and 10x because they understand what matters to us as a mutual – our customers. Working on this together is an exciting step forward in building the digital service and technology we want for the future. It's based on the simple premise of helping our customers in the way that suits them best. As expectations grow and technology evolves, we want to make sure we're right there with them, responsive and ready for what's next in their financial lives - whether that's buying their home or growing their savings for a more secure future.'
West Brom Building Society is the eighth largest building society in the UK and has been supporting its customers for over 175 years since it was founded in 1849. The adoption of Converge™ by Deloitte, fully integrated to 10x Banking's platform, will enable West Brom to unify its systems on a cloud-native architecture designed for mutuals. It will enable rapid product launches and allow customers to transact as they prefer - without incurring outsized complexity, cost and risk. Converge™ by Deloitte is a modern composable accelerator designed to help banks and building societies deliver new digital capabilities at pace.
The relationship between West Brom, Deloitte and 10x Banking, encompasses a multi-phase transformation strategy, enhancing West Brom's digital savings products, migrating existing accounts to Converge™ and the 10x platform, and unlocking greater value across its mortgage portfolio.
Jonathan Gray, UK Head of Banking Technology and Transformation at Deloitte said: 'Building societies play a prominent role in the UK savings and mortgage sector, combining financial stewardship with social purpose. We're proud to be working with West Brom Building Society and 10x Banking to facilitate the modernisation of the society's digital capability and core systems, so that they can continue to deliver value for their 400,000+ members.'
Unlike traditional all-in-one systems, 10x's platform lets mutuals tailor their products using a wide range of ready-made modules, which take away all of the unnecessary complexity, ideal for institutions balancing lean IT resources with the need to differentiate and innovate at scale and speed.
Antony Jenkins, Founder and CEO of 10x Banking, said: 'The West Brom's transformation is a milestone for the sector. Our meta core platform lets mutuals futureproof their operations while staying true to their purpose. As we approach the sector's 250th anniversary, this partnership exemplifies how - with the right cloud-native core technology in place – heritage, social purpose and innovation can coexist and deliver world-class financial solutions.'
West Brom Building Society, Deloitte and 10x Banking will be attending the 2025 Building Societies Annual Conference, hosted in Birmingham between 7 and 8 May.
Notes to editors
About the West Brom
The West Brom is the UK's eighth largest building society and is a leading provider of financial services. Proudly independent, West Brom Building Society is owned by and run for the benefit of its customers. Since its foundation in 1849, the Society's fundamental principles have been, and remain, to offer people the opportunity to buy their own homes and save for the future.
About 10x Banking
10x Banking is a cloud-native core banking platform for financial institutions and their partners. Founded by former banking executives and built by technologists, the 10x Banking platform empowers its customers with best-in-class security, scalability and speed.
Proven across transformational deployments including Westpac, Chase and Old Mutual, 10x Banking offers banks the fastest, most cost-effective and derisked path to full cloud-native transformation through its unique 'meta core' approach. Its scalable, resilient, and flexible technology is built to empower financial institutions to better serve their customers and communities. 10x Banking is a B-Corp certified business with local presence in London, UK, Sydney, Australia and Singapore and is funded by a portfolio of world-class investors including BlackRock and J.P. Morgan.
For more information, visit https://www.10xbanking.com and follow us on LinkedIn.
About Deloitte
In this press release references to 'Deloitte' are references to one or more of Deloitte Touche Tohmatsu Limited ('DTTL') a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see deloitte.com/about for a detailed description of the legal structure of DTTL and its member firms.
Deloitte LLP is a subsidiary of Deloitte NSE LLP, which is a member firm of DTTL, and is among the UK's leading professional services firms.
The information contained in this press release is correct at the time of going to press.
For more information, please visit www.deloitte.co.uk.
Member of Deloitte Touche Tohmatsu Limited.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Aera Technology Advances People-Centric Decision Intelligence with Agentic AI
LONDON--(BUSINESS WIRE)--Today at AeraHUB 25 London, the premier decision intelligence summit, Aera Technology will announce a major release of its industry-leading Aera Decision Cloud™, introducing a new wave of Agentic AI capabilities that empower users across roles and experience levels to harness AI to make smarter, faster decisions at scale. 'Aera Decision Cloud is the only platform that unifies the full decision-making context — blending structured and unstructured enterprise data, human expertise, and the reasoning capabilities of large language models." Fred Laluyaux, CEO, Aera Technology Share With this release, Aera Technology expands the frontier of people-centric decision intelligence. From the frontlines to the back office, any users can now tap the power of agents to build Aera Skills™ decision logic with natural language prompting — expanding decision-making use cases and unlocking value. A new AI-powered Data Wizard also allows data to be uploaded and categorized in seconds, and an enhanced Aera Chat interface delivers real-time insights, bringing the power of AI-driven decision-making directly into users' hands. 'Aera Decision Cloud is the only platform that unifies the full decision-making context — blending structured and unstructured enterprise data, human expertise, and the reasoning capabilities of large language models,' said Fred Laluyaux, Co-Founder, President, and CEO of Aera Technology. 'By putting these advanced capabilities directly in the hands of users, we're helping organizations achieve new levels of speed and agility in an increasingly complex world.' Meeting the Moment: AI for Today's Enterprise Challenges This comes at a pivotal time, when the speed and precision of decision execution can determine business success — and organizations face ongoing talent shortages, reskilling needs and increasing pressure to achieve tangible outcomes using AI technologies. Aera Technology's latest release redefines how decisions are made. By placing humans — regardless of technical expertise — at the center of creating AI-powered decision flows, Aera enables a shift from people doing data analysis to people architecting decision automation and overseeing action. This shift empowers business experts to increase their productivity and strategic impact. Key Innovations Rapid Skill Creation: Build Aera Skills™ with embedded AI agents that reason and act based on natural language instructions with built-in guardrails that ensure transparency, accountability, and governance. Any Data, Any Format: Tap into both structured and unstructured data sources — from transactional systems to PDFs and emails — to inform context-rich decisions. Enhanced Aera Cha t: Ask complex, data-driven questions in natural language and receive precise, actionable answers — with execution capabilities built directly into the chat. Smart Data Wizard: Upload data in seconds. The Data Wizard automatically classifies and prepares it for use — no technical training required. Key Benefits Data-Ready from Any Source: Seamlessly integrates structured and unstructured data — from systems, documents, and emails — to automate complex processes like claims management, procurement negotiations, and contract compliance. From Coding to Prompting: Accelerates time to value by defining decision intent in natural language. Agentic AI handles reasoning and generates decision logic. Autonomous, Scalable Collaboration: Communicates and coordinates across people, systems, and vendors, automating decision processes, such as negotiating order modifications. Fast Time to Action: Detects decision triggers, simulates alternatives, and executes actions autonomously. Join Us and See it in Action AeraHUB 25 London: The Decision Intelligence Summit June 11, 2025 | The Brewery, 52 Chiswell Street, London View the session lineup Learn more about Aera agentic decision intelligence Follow Aera Technology on LinkedIn for live updates and insights from the event. About Aera Technology Aera Technology, the decision intelligence company, created Aera, the first decision intelligence agent. Real-time and always-on, Aera understands how a business works, makes actionable recommendations, predicts business outcomes, executes decisions at scale, and learns from every decision. Supporting the full spectrum of decisions, from operational to strategic, Aera is powered by Aera Decision Cloud™ and its composable Aera Skills™. By empowering the world's leading companies to optimize decisions across the value chain, Aera is enabling a more sustainable, intelligent, and efficient world. Learn more at
Yahoo
2 hours ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
2 hours ago
- Business Upturn
Biotalys Reports Progress in the Regulatory Review of EVOCA in both US and EU
By GlobeNewswire Published on June 11, 2025, 10:00 IST Ghent, BELGIUM, June 11, 2025 (GLOBE NEWSWIRE) — Press release Biotalys (Euronext – BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, is pleased to announce progress in the regulatory approval procedures in both the United States and Europe of its first protein-based biocontrol product, EVOCA™*. In the US, Biotalys received a communication from the Environmental Protection Agency (EPA) that the company has provided responses to all the agency's requests for additional information. The EPA currently projects it will complete the scientific review of the EVOCA dossier later this summer and make a regulatory decision by September 30th, 2025. In Europe, Biotalys is pleased to confirm that both the Dutch Board for Authorisation of Plant Protection Products (CTGB) and the Dutch Institute for Health and Environment (RIVM) have now provided positive evaluations of EVOCA's regulatory dossier, paving the way for the peer review phase at the European level. In their review, both Dutch authorities have classified EVOCA's active ingredient as low risk based on the current data. This classification is important as it recognizes the active ingredient's safety profile and aligns with Biotalys' commitment to delivering sustainable, effective solutions for crop protection. No critical areas of concern were identified and therefore the Netherlands, as rapporteur Member State, proposes that the active ingredient of EVOCA can be approved in Europe, subject to the provision of certain additional data during the peer review phase. Biotalys' current assessment is that a regulatory decision in the European Union can be expected in the second half of 2026. Kevin Helash, Chief Executive Officer of Biotalys, said: 'We are pleased with the regulatory progress in both the US and EU, and look forward to a favorable outcome. An approval decision would be a major milestone for our company and a validation for our unique AGROBODY™ technology platform. This platform has the potential to develop many more protein-based biocontrol solutions for growers to fight key pests and diseases in agriculture. I am very grateful for the thorough review and guidance by the regulatory agencies, and for the hard work by our team to generate and provide the required scientific data on our innovative product.' The first biocontrol developed on Biotalys' AGROBODY™ technology platform, EVOCA helps safely control fungal diseases Botrytis (grey mold) and powdery mildew for fruit and vegetable growers looking to add effective, biodegradable solutions to their integrated pest management (IPM) initiatives to reduce chemical applications. * EVOCA™: Pending Registration. This product is not currently registered for sale or use in the European Union, the United States or elsewhere and is not being offered for sale. About Biotalys Biotalys is an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for the protection of crops and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on For further information, please contact: Toon Musschoot, Head of IR & CommunicationT: +32 (0)9 274 54 00 E: [email protected] Important Notice Biotalys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the annual report on the consolidated annual accounts published on the company's website. This announcement contains statements which are 'forward-looking statements' or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'aim', 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. Biotalys' actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
